Raymond James Trust’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $3.82M | Buy |
45,519
+1,409
| +3% | +$108K | 0.08% | 214 |
|
|
2024
Q2 | $3.03M | Buy |
44,110
+2,423
| +6% | +$162K | 0.07% | 232 |
|
|
2024
Q1 | $3.05M | Sell |
41,687
-1,307
| -3% | -$101K | 0.07% | 235 |
|
|
2023
Q4 | $3.48M | Buy |
42,994
+4,197
| +11% | +$327K | 0.09% | 199 |
|
|
2023
Q3 | $2.91M | Buy |
38,797
+1,892
| +5% | +$146K | 0.09% | 210 |
|
|
2023
Q2 | $2.85M | Sell |
36,905
-3,676
| -9% | -$293K | 0.08% | 219 |
|
|
2023
Q1 | $3.37M | Sell |
40,581
-6,780
| -14% | -$562K | 0.11% | 180 |
|
|
2022
Q4 | $4.07M | Sell |
47,361
-2,183
| -4% | -$173K | 0.14% | 147 |
|
|
2022
Q3 | $3.06M | Sell |
49,544
-590
| -1% | -$37.2K | 0.11% | 170 |
|
|
2022
Q2 | $3.1M | Buy |
50,134
+2,154
| +4% | +$133K | 0.11% | 177 |
|
|
2022
Q1 | $2.85M | Buy |
47,980
+1,977
| +4% | +$126K | 0.09% | 211 |
|
|
2021
Q4 | $3.34M | Sell |
46,003
-4,121
| -8% | -$284K | 0.1% | 186 |
|
|
2021
Q3 | $3.5M | Buy |
50,124
+137
| +0.3% | +$9.63K | 0.12% | 166 |
|
|
2021
Q2 | $3.44M | Sell |
49,987
-77
| -0.2% | -$5.14K | 0.11% | 170 |
|
|
2021
Q1 | $3.23M | Buy |
50,064
+225
| +0.5% | +$14.5K | 0.11% | 169 |
|
|
2020
Q4 | $2.9M | Buy |
49,839
+4,985
| +11% | +$301K | 0.11% | 167 |
|
|
2020
Q3 | $2.83M | Buy |
44,854
+8,648
| +24% | +$600K | 0.12% | 151 |
|
|
2020
Q2 | $2.79M | Sell |
36,206
-6,575
| -15% | -$504K | 0.13% | 144 |
|
|
2020
Q1 | $3.2M | Buy |
42,781
+4,623
| +12% | +$319K | 0.19% | 118 |
|
|
2019
Q4 | $2.48M | Sell |
38,158
-143
| -0.4% | -$9.31K | 0.12% | 168 |
|
|
2019
Q3 | $2.43M | Buy |
38,301
+17,465
| +84% | +$1.14M | 0.13% | 162 |
|
|
2019
Q2 | $1.41M | Sell |
20,836
-1,818
| -8% | -$120K | 0.08% | 229 |
|
|
2019
Q1 | $1.47M | Sell |
22,654
-1,233
| -5% | -$82K | 0.08% | 210 |
|
|
2018
Q4 | $1.49M | Sell |
23,887
-582
| -2% | -$40.7K | 0.1% | 204 |
|
|
2018
Q3 | $1.89M | Buy |
24,469
+1,746
| +8% | +$132K | 0.11% | 192 |
|
|
2018
Q2 | $1.61M | Sell |
22,723
-304
| -1% | -$21.5K | 0.1% | 207 |
|
|
2018
Q1 | $1.74M | Buy |
23,027
+434
| +2% | +$34.5K | 0.12% | 177 |
|
|
2017
Q4 | $1.62M | Sell |
22,593
-3,798
| -14% | -$288K | 0.11% | 190 |
|
|
2017
Q3 | $2.14M | Buy |
26,391
+765
| +3% | +$58.5K | 0.15% | 141 |
|
|
2017
Q2 | $1.81M | Sell |
25,626
-260
| -1% | -$17.3K | 0.14% | 165 |
|
|
2017
Q1 | $1.76M | Buy |
25,886
+3,273
| +14% | +$230K | 0.13% | 164 |
|
|
2016
Q4 | $1.62M | Buy |
22,613
+5,077
| +29% | +$377K | 0.13% | 172 |
|
|
2016
Q3 | $1.39M | Buy |
17,536
+1,503
| +9% | +$122K | 0.12% | 173 |
|
|
2016
Q2 | $1.34M | Buy |
16,033
+744
| +5% | +$66K | 0.12% | 174 |
|
|
2016
Q1 | $1.41M | Sell |
15,289
-3,097
| -17% | -$279K | 0.13% | 161 |
|
|
2015
Q4 | $1.86M | Buy |
18,386
+3,309
| +22% | +$344K | 0.17% | 131 |
|
|
2015
Q3 | $1.48M | Buy |
15,077
+563
| +4% | +$62.5K | 0.17% | 132 |
|
|
2015
Q2 | $1.7M | Buy |
14,514
+436
| +3% | +$47.6K | 0.18% | 131 |
|
|
2015
Q1 | $1.38M | Sell |
14,078
-456
| -3% | -$46.3K | 0.15% | 154 |
|
|
2014
Q4 | $1.37M | Buy |
14,534
+3,846
| +36% | +$398K | 0.15% | 154 |
|
|
2014
Q3 | $1.14M | Buy |
10,688
+782
| +8% | +$76.6K | 0.13% | 170 |
|
|
2014
Q2 | $821K | Sell |
9,906
-466
| -4% | -$36.3K | 0.09% | 214 |
|
|
2014
Q1 | $735K | Sell |
10,372
-285
| -3% | -$22.4K | 0.09% | 226 |
|
|
2013
Q4 | $801K | Buy |
10,657
+290
| +3% | +$20.2K | 0.11% | 192 |
|
|
2013
Q3 | $652K | Sell |
10,367
-1,300
| -11% | -$77.7K | 0.1% | 205 |
|
|
2013
Q2 | $599K | Buy |
+11,667
| New | +$608K | 0.1% | 206 |
|
Other funds holding GILD
Raymond James Trust's GILD Position: Q3 2024 in Review
Raymond James Trust increased its Gilead Sciences (GILD) stake by 3.2% in Q3 2024, buying an estimated $108K and bringing the position to 45,519 shares worth $3.82M. The position accounts for 0.08% of the portfolio, ranked #214.
Raymond James Trust first reported a position in GILD in Q2 2013 and has held it in 46 quarters since. The position peaked at $4.07M in Q4 2022. 1,718 funds tracked by Wall St. Rank hold GILD as of Q3 2024.
- Raymond James Trust held 45,519 shares of Gilead Sciences worth $3.82M as of Q3 2024.
- Raymond James Trust bought 1,409 Gilead Sciences shares in Q3 2024, an estimated $108K.
- Gilead Sciences made up 0.08% of Raymond James Trust's portfolio in Q3 2024, its #214 holding.
- Raymond James Trust first reported a position in Gilead Sciences in Q2 2013 and has held it in 46 quarters since.
- Raymond James Trust's Gilead Sciences position peaked at $4.07M in Q4 2022.
- 1,718 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.
Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.